These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 7570296)
1. Therapeutic approaches to asthma based on VLA-4 integrin and its counter receptors. Metzger WJ Springer Semin Immunopathol; 1995; 16(4):467-78. PubMed ID: 7570296 [No Abstract] [Full Text] [Related]
2. Timing of administration of anti-VLA-4 differentiates airway hyperresponsiveness in the central and peripheral airways in mice. Kanehiro A; Takeda K; Joetham A; Tomkinson A; Ikemura T; Irvin CG; Gelfand EW Am J Respir Crit Care Med; 2000 Sep; 162(3 Pt 1):1132-9. PubMed ID: 10988142 [TBL] [Abstract][Full Text] [Related]
3. Treatment of delayed-type hypersensitivity with inhibitors of the VLA-4 integrin. Tamraz S; Arrhenius T; Chiem A; Forrest MJ; Gaeta FC; He YB; Lei J; Maewal A; Phillips ML; Vollger LW Springer Semin Immunopathol; 1995; 16(4):437-41. PubMed ID: 7570294 [No Abstract] [Full Text] [Related]
4. Design and synthesis of potent and selective inhibitors of integrin VLA-4. Wattanasin S; Weidmann B; Roche D; Myers S; Xing A; Guo Q; Sabio M; von Matt P; Hugo R; Maida S; Lake P; Weetall M Bioorg Med Chem Lett; 2001 Nov; 11(22):2955-8. PubMed ID: 11677134 [TBL] [Abstract][Full Text] [Related]
6. Urokinase-type plasminogen activator inhibits alpha 4 beta 1 integrin-mediated T lymphocyte adhesion to fibronectin independently of its catalytic activity. Olivier P; Bieler G; Müller KM; Hauzenberger D; Rüegg C Eur J Immunol; 1999 Oct; 29(10):3196-209. PubMed ID: 10540331 [TBL] [Abstract][Full Text] [Related]
7. Squaric acid derivatives as VLA-4 integrin antagonists. Porter JR; Archibald SC; Childs K; Critchley D; Head JC; Linsley JM; Parton TA; Robinson MK; Shock A; Taylor RJ; Warrellow GJ; Alexander RP; Langham B Bioorg Med Chem Lett; 2002 Apr; 12(7):1051-4. PubMed ID: 11909715 [TBL] [Abstract][Full Text] [Related]
8. The role of E-selectin, P-selectin, and very late activation antigen-4 in T lymphocyte migration to dermal inflammation. Issekutz AC; Issekutz TB J Immunol; 2002 Feb; 168(4):1934-9. PubMed ID: 11823529 [TBL] [Abstract][Full Text] [Related]
9. Synthesis of a peptidomimetic tricyclic tetrahydrobenzo[ij]quinoline as a VLA-4 antagonist. Ho WB; Broka C J Org Chem; 2000 Oct; 65(20):6743-8. PubMed ID: 11052128 [No Abstract] [Full Text] [Related]
10. Pathophysiological aspects of VLA-4 interactions and possibilities for therapeutical interventions. Kuijpers TW Springer Semin Immunopathol; 1995; 16(4):379-89. PubMed ID: 7570289 [No Abstract] [Full Text] [Related]
16. Role of the VLA-4 integrin in leucocyte recruitment and bronchial hyperresponsiveness in the guinea-pig. Milne AA; Piper PJ Eur J Pharmacol; 1995 Aug; 282(1-3):243-9. PubMed ID: 7498283 [TBL] [Abstract][Full Text] [Related]